Literature DB >> 26171042

Expression profile of Twist, vascular endothelial growth factor and CD34 in patients with different phases of osteosarcoma.

Pengfei Lei1, Dengfeng Ding1, Jie Xie1, Long Wang1, Qiande Liao1, Yihe Hu1.   

Abstract

The aim of the present study was to investigate the clinical significance of Twist, vascular endothelial growth factor (VEGF) and CD34 expression in osteosarcoma (OS) in order to elucidate potential therapeutic targets for the treatment of OS. Immunohistochemistry was performed to detect the protein expression of Twist, VEGF and CD34 in OS and osteochondroma (OC) tissues. The ratio of the protein expression of Twist and VEGF in OS and OC tissues as well as at different phases of OS was compared using chi-squared tests. Microvessel density (MVD), as determined by CD34 labeling, in OS and OC tissue as well as at different phases of OS was compared using the Student's t-test. In addition, associations between Twist, VEGF and MVD were assessed using the Spearman's rank correlation test. The results revealed that out of the 32 OS tissues examined, 56.25% exhibited Twist positive expression, 71.88% exhibited VEGF positive expression and the MVD was increased compared with that of the OC tissue. The positive rate of Twist and VEGF expression in phase III OS tissues was significantly increased compared with that in phase I/II OS tissues (Twist: χ2=5.732, P=0.018; VEGF: χ2=7.513, P=0.006). The MVD in phase III OS tissues (31.08±3.36 per field) was significantly higher compared with that of the phase I/II OS tissues (41.2±4.17 per field; t=7.536, P<0.001). Spearman's rank correlation analysis revealed that Twist expression was positively associated with VEGF expression (r=0.371, P=0.002) and with MVD (r=0.393, P=0.001) in OS; in addition, VEGF expression was found to have a positive correlation with MVD (r=0.469, P=0.001). In conclusion, the results of the present study demonstrated that OS tissues exhibited elevated Twist and VEGF expression as well as MVD compared with OC tissue. In addition, metastatic OS (phase III) exhibited an increased positive rate of Twist and VEGF expression as well as MVD values compared with non-metastatic OS (phase I/II). Furthermore associations were detected between Twist and VEGF expression as well as VEGF and MVD. Therefore, inhibition of Twist expression may have potential therapeutic use for the treatment of OS.

Entities:  

Keywords:  CD34; Twist; metastatic; osteosarcoma; vascular endothelial growth factor

Year:  2015        PMID: 26171042      PMCID: PMC4487166          DOI: 10.3892/ol.2015.3246

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  33 in total

1.  Twist overexpression induces in vivo angiogenesis and correlates with chromosomal instability in breast cancer.

Authors:  Yelena Mironchik; Paul T Winnard; Farhad Vesuna; Yoshinori Kato; Flonne Wildes; Arvind P Pathak; Scott Kominsky; Dmitri Artemov; Zaver Bhujwalla; Paul Van Diest; Horst Burger; Carlotta Glackin; Venu Raman
Journal:  Cancer Res       Date:  2005-12-01       Impact factor: 12.701

2.  Endoglin (CD105) is a useful marker for evaluating microvessel density and predicting prognosis in esophageal squamous cell carcinoma.

Authors:  Toshihide Sakurai; Hiroshi Okumura; Masataka Matsumoto; Yasuto Uchikado; Tetsuhiro Owaki; Yoshiaki Kita; Tetsuro Setoyama; Itaru Omoto; Yuko Kijima; Sumiya Ishigami; Shoji Natsugoe
Journal:  Anticancer Res       Date:  2014-07       Impact factor: 2.480

3.  A new twist on transcriptional bursting.

Authors:  David Levens; Daniel R Larson
Journal:  Cell       Date:  2014-07-17       Impact factor: 41.582

4.  Twist modulates lymphangiogenesis and correlates with lymph node metastasis in supraglottic carcinoma.

Authors:  Su-Mei Lu; Liang Yu; Jia-Jun Tian; Ju-Ke Ma; Jian-Feng Li; Wei Xu; Hai-Bo Wang
Journal:  Chin Med J (Engl)       Date:  2011-05       Impact factor: 2.628

Review 5.  Receptor tyrosine kinases in osteosarcoma: not just the usual suspects.

Authors:  Ashley N Rettew; Patrick J Getty; Edward M Greenfield
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

Review 6.  A systematic review of vascular endothelial growth factor expression as a biomarker of prognosis in patients with osteosarcoma.

Authors:  Ding Chen; Ye-Jia Zhang; Ke-wei Zhu; Wan-Chun Wang
Journal:  Tumour Biol       Date:  2013-04-16

Review 7.  VEGF and EMMPRIN expression correlates with survival of patients with osteosarcoma.

Authors:  Quan Zhou; Yong Zhu; Zhansheng Deng; Haitao Long; Shaoxian Zhang; Xingli Chen
Journal:  Surg Oncol       Date:  2011-03       Impact factor: 3.279

8.  Prognostic significance of treatment-induced pathologic necrosis in extremity and truncal soft tissue sarcoma after neoadjuvant chemoradiotherapy.

Authors:  John T Mullen; Francis J Hornicek; David C Harmon; Kevin A Raskin; Yen-Lin Chen; Jackie Szymonifka; Beow Y Yeap; Edwin Choy; Thomas F DeLaney; G Petur Nielsen
Journal:  Cancer       Date:  2014-07-31       Impact factor: 6.860

9.  CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: analysis within a group of patients, all of whom developed lung metastasis.

Authors:  Yoshinao Oda; Hidetaka Yamamoto; Sadafumi Tamiya; Shuichi Matsuda; Kazuhiro Tanaka; Ryohei Yokoyama; Yukihide Iwamoto; Masazumi Tsuneyoshi
Journal:  Mod Pathol       Date:  2006-05       Impact factor: 7.842

10.  Twist2 contributes to cisplatin-resistance of ovarian cancer through the AKT/GSK-3β signaling pathway.

Authors:  Tian Wang; Yan Li; Abidan Tuerhanjiang; Wenwen Wang; Zhangying Wu; Ming Yuan; Mayinuer Maitituoheti; Shixuan Wang
Journal:  Oncol Lett       Date:  2014-01-21       Impact factor: 2.967

View more
  10 in total

1.  Cytoplasmic expression of Twist1, an EMT-related transcription factor, is associated with higher grades renal cell carcinomas and worse progression-free survival in clear cell renal cell carcinoma.

Authors:  Arezoo Rasti; Zahra Madjd; Maryam Abolhasani; Mitra Mehrazma; Leila Janani; Leili Saeednejad Zanjani; Mojgan Asgari
Journal:  Clin Exp Med       Date:  2017-12-04       Impact factor: 3.984

2.  [Twist regulates proliferation, migration and invasion of osteosarcoma cells in vitro].

Authors:  Yun He; Shu-Yu Fang; Yang Bi; Tong-Chuan He; Yi Wang; Si-Qi Hong
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-05-20

Review 3.  Research models and mesenchymal/epithelial plasticity of osteosarcoma.

Authors:  Xiaobin Yu; Jason T Yustein; Jianming Xu
Journal:  Cell Biosci       Date:  2021-05-22       Impact factor: 7.133

4.  Transcription factor SPZ1 promotes TWIST-mediated epithelial-mesenchymal transition and oncogenesis in human liver cancer.

Authors:  L-T Wang; S-S Chiou; C-Y Chai; E Hsi; C-M Chiang; S-K Huang; S-N Wang; K K Yokoyama; S-H Hsu
Journal:  Oncogene       Date:  2017-04-03       Impact factor: 9.867

5.  Sex-determining region Y-box protein 3 induces epithelial-mesenchymal transition in osteosarcoma cells via transcriptional activation of Snail1.

Authors:  Manle Qiu; Daoyun Chen; Chaoyong Shen; Ji Shen; Huakun Zhao; Yaohua He
Journal:  J Exp Clin Cancer Res       Date:  2017-03-23

6.  LAIR-1 overexpression inhibits epithelial-mesenchymal transition in osteosarcoma via GLUT1-related energy metabolism.

Authors:  Jinxue Zhang; Yuan Zhang; Shiyang Cheng; Yang Mu; Yongming Liu; Xin Yi; Dongxu Jiang; Yong Ding; Ran Zhuang
Journal:  World J Surg Oncol       Date:  2020-06-20       Impact factor: 2.754

Review 7.  The role of vascular endothelial growth factor as a prognostic and clinicopathological marker in osteosarcoma: a systematic review and meta-analysis.

Authors:  Chao Zhang; Lin Wang; Chuang Xiong; Runhan Zhao; Hao Liang; Xiaoji Luo
Journal:  J Orthop Surg Res       Date:  2021-12-28       Impact factor: 2.359

8.  Is overexpression of TWIST, a transcriptional factor, a prognostic biomarker of head and neck carcinoma? Evidence from fifteen studies.

Authors:  Xianlu Zhuo; Huanli Luo; Aoshuang Chang; Dairong Li; Houyu Zhao; Qi Zhou
Journal:  Sci Rep       Date:  2015-12-10       Impact factor: 4.379

Review 9.  Microenvironmental Targets in Sarcoma.

Authors:  Monika Ehnman; Olle Larsson
Journal:  Front Oncol       Date:  2015-11-04       Impact factor: 6.244

Review 10.  Transforming Growth Factor-β Signaling Plays a Pivotal Role in the Interplay Between Osteosarcoma Cells and Their Microenvironment.

Authors:  Franck Verrecchia; Françoise Rédini
Journal:  Front Oncol       Date:  2018-04-30       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.